Pneumococcal Vaccines Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
Description
Pneumococcal Vaccines Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
Pneumococcal disease is a common and often mild infection that includes conditions such as middle ear infection, a blood infection, pneumonia, and bacterial meningitis. However, the disease can sometimes result in severe and fatal health problems. Pneumococcal vaccines offer protection against streptococcus pneumonia, which is a causative agent. The vaccine is available in two types as conjugate vaccine and polysaccharide vaccine. Pneumococcal vaccines are administered through intramuscular route. Conjugate vaccines are administered to infants, while polysaccharide vaccines are effective in healthy adults.
Market Dynamics
Pharmaceutical companies are reluctant to invest in production of new vaccines, owing to very less returns. Therefore, vendors are focused on joining Advance Market Commitment (AMC), an innovative financing program. Under AMC, international agencies pay a premium above the incremental production cost for initial doses sold to emerging economies in exchange of continuous supply of vaccines from vendors at sustainable prices for long term.
In 2010, Pfizer entered into the AMC program and agreed to supply 300 Mn doses of PCV13 for pneumococcal disease. Subsequently, Pfizer entered into two additional agreements with the AMC expanding its commitment with an additional 440 Mn doses, for a total commitment of 740 Mn doses of PCV13 vaccine until 2025.
Moreover, in 2015, Pfizer reduced prices of four new dose vial presentations of PCV13, which was expected to be introduced under the AMC program in 2016. The prices were reduced by 20% per-dose i.e., from US$ 3.30 per dose to US$ 3.10 per dose.
Key features of the study:
This report provides in-depth analysis of the pneumococcal vaccine market, market size (US$ Mn) and cumulative annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global pneumococcal vaccine market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include, Pfizer, Inc., Merck & Co. Inc., and GlaxoSmithKline plc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global pneumococcal vaccine market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for pneumococcal vaccine market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
Global Pneumococcal Vaccine Market, By Vaccine Type:
PCV10
PCV13
PPSV23
Global Pneumococcal Vaccine Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Pneumococcal Vaccine Market, By Region:
North America
By Country:
U.S.
Canada
By Vaccine Type:
PCV10
PCV13
PPSV23
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Vaccine Type:
PCV10
PCV13
PPSV23
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Vaccine Type:
PCV10
PCV13
PPSV23
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Vaccine Type:
PCV10
PCV13
PPSV23
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Vaccine Type:
PCV10
PCV13
PPSV23
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country:
South Africa
Central Africa
North Africa
By Vaccine Type:
PCV10
PCV13
PPSV23
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Pfizer, Inc.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Merck & Co. Inc.
GlaxoSmithKline plc
“*” marked represents similar segmentation in other categories in the respective section.
Pneumococcal disease is a common and often mild infection that includes conditions such as middle ear infection, a blood infection, pneumonia, and bacterial meningitis. However, the disease can sometimes result in severe and fatal health problems. Pneumococcal vaccines offer protection against streptococcus pneumonia, which is a causative agent. The vaccine is available in two types as conjugate vaccine and polysaccharide vaccine. Pneumococcal vaccines are administered through intramuscular route. Conjugate vaccines are administered to infants, while polysaccharide vaccines are effective in healthy adults.
Market Dynamics
Pharmaceutical companies are reluctant to invest in production of new vaccines, owing to very less returns. Therefore, vendors are focused on joining Advance Market Commitment (AMC), an innovative financing program. Under AMC, international agencies pay a premium above the incremental production cost for initial doses sold to emerging economies in exchange of continuous supply of vaccines from vendors at sustainable prices for long term.
In 2010, Pfizer entered into the AMC program and agreed to supply 300 Mn doses of PCV13 for pneumococcal disease. Subsequently, Pfizer entered into two additional agreements with the AMC expanding its commitment with an additional 440 Mn doses, for a total commitment of 740 Mn doses of PCV13 vaccine until 2025.
Moreover, in 2015, Pfizer reduced prices of four new dose vial presentations of PCV13, which was expected to be introduced under the AMC program in 2016. The prices were reduced by 20% per-dose i.e., from US$ 3.30 per dose to US$ 3.10 per dose.
Key features of the study:
This report provides in-depth analysis of the pneumococcal vaccine market, market size (US$ Mn) and cumulative annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global pneumococcal vaccine market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include, Pfizer, Inc., Merck & Co. Inc., and GlaxoSmithKline plc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global pneumococcal vaccine market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for pneumococcal vaccine market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
Global Pneumococcal Vaccine Market, By Vaccine Type:
PCV10
PCV13
PPSV23
Global Pneumococcal Vaccine Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Pneumococcal Vaccine Market, By Region:
North America
By Country:
U.S.
Canada
By Vaccine Type:
PCV10
PCV13
PPSV23
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Vaccine Type:
PCV10
PCV13
PPSV23
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Vaccine Type:
PCV10
PCV13
PPSV23
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Vaccine Type:
PCV10
PCV13
PPSV23
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Vaccine Type:
PCV10
PCV13
PPSV23
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country:
South Africa
Central Africa
North Africa
By Vaccine Type:
PCV10
PCV13
PPSV23
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Pfizer, Inc.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Merck & Co. Inc.
GlaxoSmithKline plc
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
150 Pages
- 1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Vaccine Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Pipeline Analysis
- Strategic Collaborations
- Government Fundings and Support
- Reimbursement Scenario
- GAVI and PATH Program Details
- Supply Shortage Scenario
- Epidemiology
- Target Age Group Analysis
- PEST Analysis
- 4. Global Pneumococcal Vaccines Market, By Vaccine Type, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- PCV10
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- PCV13
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- PPSV23
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- 5. Global Pneumococcal Vaccines Market, By Distribution Channel, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- 6. Global Pneumococcal Vaccines Market, By Region, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, By Region, 2017 - 2028
- Regional Trends
- North America
- Market Size and Forecast, By Vaccine Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Vaccine Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Vaccine Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Vaccine Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Vaccine Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- Northern Africa
- Central Africa
- South Africa
- Middle East
- Market Size and Forecast, By Vaccine Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- GCC Countries
- Israel
- Rest of Middle East
- 7. Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Merck & Co. Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- GlaxoSmithKline plc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Analyst Views
- 8. Section
- References
- Research Methodology
- About us and Sales Contact
- *Browse 26 market data tables and 32 figures on "Pneumococcal Vaccines Market” - Global forecast to 2028”.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
